Search Results
Nov 21, 2025, 08:00 ET 9amHealth to Expand Access to Obesity Management Treatment through New Employer Health Benefits Offering
just over half of large employers cover GLP-1 medications. Through the launch of this new offering, 9amHealth will provide a clear and predictable model that brings transparency to medication
More news about: 9amHealth
Nov 21, 2025, 06:22 ET Weekly Recap: 14 Health Press Releases You Need to See
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and VomitingThis study, which pre-treated patients with either tradipitant or placebo before administering a 1 mg
More news about: PR Newswire
Nov 21, 2025, 05:00 ET Sunlight.com: Survey Finds 4 in 10 GLP-1 Users Will Delay or Skip a Dose for Thanksgiving
that a significant share of GLP-1 users are preparing to modify their medication schedule for Thanksgiving. The study, which surveyed 1,250 current GLP-1 users in November 2024, shows that 40% plan to alter their
More news about: Sunlight
Nov 20, 2025, 18:16 ET Boston's MENU ORDER AI Saw Rapid Early Traction, Strong Downloads, Paid Users, and Rising Interest From Restaurants and Medical Providers
GLP-1 adoption continues to influence dining behavior nationwide. MENU ORDER AI's QR-code pilot program gives restaurants a way to provide instant menu transparency at the table, helping guests identify high-protein and GLP-1 friendly
More news about: MENU - ORDER AI
Nov 20, 2025, 17:31 ET Alcohol Use Disorder Market to Grow Rapidly at a 13.6% CAGR by 2034 Owing to Rising Disease Prevalence, Significant Advancements in Genetically-targeted Therapies, along with Innovative Treatments such as GLP-1 Receptor Agonists | DelveInsight
content:https://www.prnewswire.com/news-releases/alcohol-use-disorder-market-to-grow-rapidly-at-a-13-6-cagr-by-2034-owing-to-rising-disease-prevalence-significant-advancements-in-genetically-targeted-therapies-along-with-innovative-treatments-such-as-glp-1-receptor-agonists--302621236.htmlSOURCE
More news about: DelveInsight Business Research, LLP
Nov 20, 2025, 15:00 ET Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
obesity models, GV101 reduces lipid droplets both in mouse and human adipocytes. Graviton's ROCK2 inhibitors decrease weight similarly to GLP-1 RAs with relative lean mass preservation. Clinical
More news about: Graviton Bioscience
Nov 20, 2025, 13:05 ET Beat the End-of-Year Healthcare Rush with FSA- and HSA-eligible Telehealth at FSA Store® and HSA Store®
off first month, plus free shipping. Powered by Forbes Health, MEDVi delivers GLP-1 prescription medications and free monthly care coaching services designed to help users achieve measurable weight loss results. Note: $120 discount
More news about: Health-E Commerce
Nov 20, 2025, 06:30 ET NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as First-in-Class Drugs Redefine Fatty Liver Disease Management | According to DataM Intelligence
MASH due to overlapping patient populations. GLP-1 agonists hold an estimated 35% commercial potential of the entire future market. Survodutide, with dual GLP-1/glucagon agonism, is expected to drive rapid fat reduction,
More news about: DataM Intelligence 4 Market Research LLP
Nov 19, 2025, 19:00 ET Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
(Lilly) for the development and potential commercialization of mazdutide, a dual GCG/GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing
More news about: Innovent Biologics
Nov 19, 2025, 09:53 ET LEMME NAMED 2025 BRAND OF THE YEAR BY WWD
says Simon Huck, Partner at Lemme. This recognition follows the success of Lemme's top-selling GLP-1 support supplement, Lemme GLP-1 Daily, which earned Product of the Year last year for its cutting-edge science and clinically studied ingredients.
More news about: Lemme
Nov 19, 2025, 09:17 ET Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
with state-of-the-art Class 100,000 cleanroom environments, ensuring high standards of quality and a smooth transition from research-grade to GLP/GMP-compliant workflows. About Tsingke Beijing Tsingke Biotech
More news about: Beijing Tsingke Biotech Co., Ltd.
Nov 19, 2025, 09:17 ET Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
with state-of-the-art Class 100,000 cleanroom environments, ensuring high standards of quality and a smooth transition from research-grade to GLP/GMP-compliant workflows. About Tsingke
More news about: Beijing Tsingke Biotech Co., Ltd.
Nov 19, 2025, 02:55 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
About GLP-1 and Dual GLP-1/GIP Agonists Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce
More news about: Viking Therapeutics, Inc.
Nov 19, 2025, 02:00 ET The Global Wellness Economy Hits a Record $6.8 Trillion and Is Forecast to Reach $9.8 Trillion by 2029
more than doubled in the last five years to reach $86 billion, to the contraction of the weight loss services market in 2024 (-1.1%) with the boom in GLP-1s. Which Wellness Markets Will Grow Fastest? (Projections 2024-2029)
More news about: GLOBAL WELLNESS INSTITUTE
Nov 18, 2025, 08:15 ET Pipe17 Joins Commerce Operations Foundation as Founding Member to Advance Open Standards for the AI-Native Commerce Era
Platform that unifies orders, inventory, products and fulfillments across commerce channels, marketplaces, ERPs and fulfillment partners. Backed by GLP Capital, LFX Ventures, and Blumberg Capital, Pipe17 helps innovative brands like Allbirds, Wyze and MaryRut, and leading 3PLs like FedEx, Radial, and
More news about: Pipe17
Nov 18, 2025, 06:35 ET The Next Generation 'OS' of Sweetening Has Arrived
efforts to reduce sugar in school lunch programs, investigating the definition of Ultra Processed Foods, the explosive growth of weight-loss GLP-1 drug use and MAHA's moves to force the removal of artificial food colors from packaged foods are just the tip of the transition iceberg. These events,
More news about: Oobli
Nov 17, 2025, 18:37 ET Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
"These results demonstrate tradipitant's potential to mitigate GLP-1 induced nausea and vomiting which are key contributors of the 30-50% real-world discontinuation rates for GLP-1 agonists, often before therapeutic doses are reached," said Mihael H. Polymeropoulos,
More news about: Vanda Pharmaceuticals Inc.
Nov 17, 2025, 16:31 ET Estudo da Novo Nordisk descreve associações entre o uso de Wegovy® e gastos com álcool e tabaco
percentuais nas compras de produtos de tabaco, em comparação com lares onde não havia usuários de medicamentos da classe dos agonistas do receptor GLP-1¹. Embora a causalidade direta ainda precise ser investigada, os dados indicam que os benefícios do tratamento podem transcender
More news about: Novo Nordisk
Nov 17, 2025, 11:58 ET Bariatric Surgery vs GLP-1 Medications like Ozempic or Mounjaro: Bariatric Surgeon Dr. David G. Davtyan of Weight Loss Surgery Los Angeles Weighs In on Real-World Results
Dr. David G. Davtyan of Weight Loss Surgery Los Angeles discusses how bariatric surgery continues to outperform GLP-1 medications in achieving long-term, sustainable weight loss. The release educates patients on personalized treatment options and the importance
More news about: The Weight Loss Surgery Center Of Los Angeles
Nov 17, 2025, 11:18 ET Arctx Medical Receives FDA Marketing Authorization for its Arctx Cool Catheter™ Set for Body Temperature Regulation, Releases Initial Clinical Results in Acute Pancreatitis
alcohol use disorder, high triglyceride levels, infections, and other medical conditions. A possible association between the use of popular GLP-1 receptor agonists and AP has also been reported. AP causes significant and prolonged patient discomfort, can lead to serious systemic illness, and
More news about: Arctx
Nov 17, 2025, 07:45 ET Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month
today, Novo Nordisk is bringing these prices to consumers months in advance of that commitment. "As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy® and Ozempic® are affordable and accessible to those who
More news about: Novo Nordisk
Nov 14, 2025, 19:48 ET Revolutionary App MENU ORDER AI Now Available on the App Store -- The First Real-Time Dining Companion for GLP-1 Users
GLP-1 medications like Zepbound and Ozempic are transforming how Americans eat. Roughly 6 percent of U.S. adults currently use GLP-1s, with adoption expected to more than double by 2027. Restaurants are already feeling the shift as GLP-1 users order smaller portions
More news about: MENU - ORDER AI
Nov 14, 2025, 09:15 ET Pritikin Longevity Center Concludes 50th Anniversary Celebration - Revealing What's Next for the Future of Healthspan
including: Consultations and lectures on how the Pritikin lifestyle works with GLP-1-based therapies to achieve sustainable results Emerging science on gut microbiome testing Launching
More news about: Pritikin Longevity Center
Nov 13, 2025, 17:31 ET ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight
formulations demonstrated favorable safety profiles, comparable to or superior to those of current GLP-1R agonists. Preclinical studies on a novel combination therapy of ASC31 (a dual GLP-1R and GIPR peptide agonist) with ASC47 (a thyroid hormone receptor beta-selective small
More news about: DelveInsight Business Research, LLP
Nov 13, 2025, 10:00 ET Landmark JPAD Special Issue Highlights How Combination Therapies, Underpinned by New Era of Research, Are Poised to Redefine Alzheimer's Treatment
pipeline, comprising 11% of all current trials. And many promising candidates remain on the horizon, including GLP-1 drugs like semaglutide. "We have entered a new era in Alzheimer's research, one that is embracing the complexity of the disease
More news about: Alzheimer's Drug Discovery Foundation